Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews lichen planopilaris, its presentation, and treatment challenges, and emphasizes the need for more research into its pathogenesis and therapy efficacy; it reports no new findings.

This review compiles existing data on frontal fibrosing alopecia and highlights the promise of 5-alpha reductase inhibitors as a treatment option, while noting the need for clarity on its cause and progression.

This review discusses clinical presentations and interventions for alopecia in women of color, highlighting the importance of early recognition and treatment but providing no new clinical results.

The study suggests hormonal factors may play a role in Frontal Fibrosing Alopecia and that treatments like oral antiandrogens and steroids could be beneficial.

This systematic review discusses the treatment characteristics and outcomes for frontal fibrosing alopecia specifically in Black patients with skin of color, addressing a gap in clinical evidence due to underrepresentation in studies.

This review discusses the evolving understanding of frontal fibrosing alopecia as a generalized skin condition with diverse manifestations, and reports no new clinical results.

The new topical product combined with finasteride significantly increased hair thickness without side effects.

Mycophenolic acid may help hair grow by activating pathways important for hair growth.

This study reports two cases of follicular lichen planus, suggesting that GLPLS and LPP may be variants of this condition based on clinical and immunofluorescent findings.

Lichen planopilaris is a rare, chronic condition causing hair loss, mainly in middle-aged women, and early treatment is important to prevent permanent baldness.

This study provides one of the first descriptions of the demographic, clinical, and therapeutic characteristics of lichen planopilaris in Chilean adults, reporting that treatment usually reduced or halted disease progression.

This study reviewed cases of Graham–Little-Piccardi–Lassueur syndrome and found that topical treatments were generally ineffective, while systemic therapies like prednisone, hydroxychloroquine, and isotretinoin led to partial hair regrowth and disease stabilization, highlighting the importance of early diagnosis and systemic therapy to improve outcomes.

In this observational study, dermoscopy was found to be a useful tool in diagnosing lichen planopilaris among patients with primary cicatricial alopecia.

The study suggests that immune privilege collapse in bulge cells and the involvement of pro-inflammatory cytokine interferon-γ contribute to hair follicle stem cell loss in lichen planopilaris.

This study found that treatment improved symptoms and stopped disease progression for 75% of lichen planopilaris patients whose follow-up data were available.

In a study reviewing 291 patients with lichen planopilaris, findings revealed that women were more commonly affected than men, cyclosporine and methotrexate were most effective in achieving remission, and 5-alpha reductase inhibitors and systemic retinoids were particularly beneficial for frontal fibrosing alopecia.

This review discusses the role of PPAR-γ in the pathogenesis of primary cicatricial alopecia, including its involvement in lichen planopilaris and treatment trials using PPAR-agonists, and reports no new clinical results.

This study suggests that decreased PPARgamma function may trigger the pathogenesis of lichen planopilaris, and PPARgamma-targeted therapy could be a potential treatment method.

This case report found that a novel botanical treatment halted disease progression and promoted hair regrowth in four patients with lichen planopilaris, indicating potential for use as a safe alternative therapy.

This review discusses lichen planopilaris in children and highlights its rarity, potential for misdiagnosis, and need for suspicion in atypical or treatment-resistant alopecia cases, but reports no new results.

This study examined 56 Thai patients with frontal fibrosing alopecia, finding frontotemporal hairline recession and eyebrow loss were common, and reported better disease stabilization with combination treatments of topical corticosteroids with hydroxychloroquine or finasteride.

This study reports that frontal fibrosing alopecia in Brazilian patients is common in postmenopausal women and often associated with hypothyroidism and facial irritation from cosmetic products.

In this study, pioglitazone treatment in patients with lichen planopilaris showed limited success, with significant improvement seen in only a minority of cases.

This study found that platelet-rich plasma may be more effective and satisfactory than topical clobetasol for treating lichen planopilaris over six months.

This study found that lichen planopilaris is associated with three core molecular pathways, which may inform new therapeutic strategies for scarring alopecia, including unique pathways like ABC transporters specific to LPP.

This article discusses the importance of early recognition of LPP due to its significant aesthetic and psychosocial effects and calls for efforts to prevent misdiagnosis.

This report describes a rare case of scarring alopecia, diagnosed as lichen planopilaris (LPP), affecting solely the limbs, highlighting the necessity for thorough evaluation of LPP beyond the scalp.

Lichen Planopilaris causes irreversible hair loss due to immune attacks on hair stem cells, but modulating PPAR-γ might help treat it.

In this study, key histologic features such as mucinous perifollicular fibroplasia were identified to aid in the diagnosis of lichen planopilaris.

This case report describes an atypical presentation of lichen planopilaris affecting only facial vellus hair, without scalp involvement, in a 46-year-old man.